The Connection Between Circulation and ‌Cancer

New research from NYU Langone ​Health reveals a concerning link between ⁤restricted blood flow and accelerated cancer ⁣growth. Published August 19, 2025, in JACC: CardioOncology, the study demonstrates ⁢that limiting ⁤blood⁣ supply – a condition known as ischemia – can considerably weaken the body’s‌ ability to ⁣fight cancer, ​effectively “prematurely aging” the immune system. This builds upon earlier work from the same team, ⁣published in⁤ 2020, which showed similar effects during ​a heart ‌attack.

Ischemia occurs when​ arteries become narrowed by fatty deposits,‌ like cholesterol, leading to inflammation and clots that impede ‌oxygen-rich blood flow.⁢ When this happens in the legs, ‌it’s known as peripheral artery‍ disease (PAD), a condition affecting millions of Americans and increasing ⁣the risk of heart⁢ attack and stroke. But⁤ the⁣ implications⁤ extend far beyond cardiovascular health, as this new research demonstrates.

How Ischemia Impacts the Immune System

Researchers ‌found that restricted blood‌ flow doesn’t just affect the immediate area; it ⁢triggers a systemic shift in immune cell populations.The study, conducted on mice with breast tumors, showed that impaired​ blood flow led to a doubling ⁢of tumor growth rates compared to mice with normal circulation. This isn’t a localized effect; the team’s findings suggest⁣ that ⁣compromised blood flow, regardless of ‌its location in the body,⁤ can drive cancer progression.

the immune system, normally adept at identifying and eliminating‌ cancer cells, relies on a balance of ​different cell‍ types. Reduced ​blood flow disrupts this balance, reprogramming stem cells in the bone marrow.Rather of producing lymphocytes – crucial T cells that directly attack⁢ cancer – the body begins to generate more “myeloid” cells (monocytes, macrophages, neutrophils) which suppress the immune response. This⁢ shift ‍creates an environment where cancer can thrive.

This immune suppression isn’t limited to the bone marrow.The environment *within* the ⁤tumor itself‍ also changes, accumulating immune-suppressive cells like Ly6Chi monocytes, M2-like F4/80+ MHCIIlo macrophages, and regulatory T cells, ⁣effectively shielding​ the cancer from attack.

The Long-Lasting effects of Ischemia

What’s particularly concerning is the longevity of these⁢ immune ⁣changes. The research revealed that ischemia doesn’t just cause ⁤a temporary shift; it alters gene expression and even reorganizes chromatin – the structure that controls ​DNA access – making it harder for immune cells to activate the ‍genes needed to fight cancer. This suggests that even temporary​ disruptions⁢ in blood flow can have lasting consequences for immune function and cancer risk.

“Our study shows that impaired blood flow drives cancer growth regardless⁤ of where​ it happens in the body. This link between peripheral artery disease and breast cancer growth underscores the critical importance of addressing metabolic‍ and vascular risk factors as part of a extensive cancer treatment strategy.”

Kathryn J.Moore,⁣ PhD, ​Jean ​and ‌David Blechman Professor of Cardiology, NYU Grossman School of Medicine

Implications for Prevention and Treatment

These ⁣findings open up exciting⁣ new avenues for cancer ​prevention and treatment. researchers suggest that individuals with peripheral artery disease may benefit from earlier and more frequent​ cancer screenings. Furthermore,⁣ exploring⁢ inflammation-modulating therapies to counteract the effects of ischemia could prove beneficial in slowing or preventing cancer progression.

The NYU ​Langone⁤ Health team⁣ is now working to design clinical studies ​to evaluate the effectiveness ​of inflammation-targeted therapies in counteracting the post-ischemic changes ​that drive ‍tumor growth. The full list of study authors‍ includes ⁣Jose ‍Gabriel Barcia‍ Duran, Richard Von Itter, Jessie Dalman, Brian Lim, Morgane ⁢Gourvest, Tarik Zahr, Kristin Wang, ⁣Tracy Zhang, Noah Albarracin, Whitney Rubin, Fazli ⁣K.​ Bozal, Chiara Giannarelli, Michael ​Gildea, Coen van solingen, and ⁣Kory Lavine of Washington University School​ of Medicine.